Chronic obstructive pulmonary disease costs over $50 billion and causes at least 3 million deaths globally each year.Annual NHS costs for chronic obstructive pulmonary disease (COPD) exceed £1.9 billion. Most of this cost is derived from unplanned inpatient admissions following acute disease exacerbation. The mymhelath myCOPD platform is a patient self-management tool that empowers users to manage their disease more effectively by reducing inhaler errors, increasing medication compliance
and providing structured education and guidance.
NHS Highland has secured test of change funding to evaluate the myCOPD platform and has approached the University of the Highlands and Islands for assistance in data collection, evaluation, and health economics modelling to
support subsequent health board procurement.
- Evaluate the clinical and economic impact of myCOPD during the test of change.
- Provide a cost-benefit model and analysis to facilitate downstream procurement decisions.Potential impacts and outcomesThis project will evaluate the health and economic benefits of the myCOPD digital health platform. Results will be used to evaluate the cost effectiveness of this intervention as well as its impact on overall patient health and wellbeing.